Castle Biosciences, Inc.
NASDAQ:CSTLMedical - Diagnostics & Research
+$0.04 today
- Market cap
- $1.03B
- Beta
- 1.02
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.43
Volume 0.38M
Average 0.37M
CSTL EBITDA Margin
EBITDA as a percentage of revenue.
Castle Biosciences, Inc.NASDAQ: CSTL
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -12.4%
EBITDA Margin was -12.4% in Q1 FY2026, down 16.4 pp from a year earlier. On a trailing-twelve-month basis it was -0.2%, down 12.0 pp year over year. Over 3 fiscal years it widened by 45.9 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 7 analysts of 3.6% for the fiscal year ending Dec 2026, up from 3.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -12.4%-13.6 pp QoQ
- Last fiscal yearDec 2025
- 3.3%-8.2 pp YoY
- LTMMar 2026
- -0.2%-12.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -16.4 pp | -13.3 pp | +3.0 pp |
| 1 year | -8.2 pp | +0.3 pp | +8.5 pp |
| 3 years | +45.9 pp | +3.5 pp | -42.3 pp |
| 5 years | +9.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 3.3%
- Year-over-year change
- -8.2pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.3% | -8.2pp |
| FY2024 | 2024-12-31 | 11.5% | +32.0pp |
| FY2023 | 2023-12-31 | -20.5% | +22.1pp |
| FY2022 | 2022-12-31 | -42.6% | -3.7pp |
| FY2021 | 2021-12-31 | -38.9% | — |
EBITDA Margin vs competitors
How CSTL compares with its peers on the latest reported figures
- CSTL's LTM Mar 2026 EBITDA Margin of -0.2% is the 3rd highest of the 8 companies compared; the peer median is -19.1%.
- Its year-over-year change of -12.0 pp is the 6th highest of 8, against a peer median of +5.8 pp.
- Over three fiscal years its change of +45.9 pp compares with a peer median of +53.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 23.1% | +13.6 pp | +20.8 pp | |
| LTM Jun 2026 | 1.7% | +5.8 pp | +10.8 pp | |
| LTM Mar 2026 | -0.2% | -12.0 pp | +45.9 pp | |
| FY2025 | -13.0% | +11.5 pp | +85.2 pp | |
| LTM Mar 2026 | -19.1% | +17.8 pp | +110.1 pp | |
| LTM Sep 2026 | -34.5% | +4.7 pp | +98.7 pp | |
| LTM Mar 2026 | -40.3% | -32.6 pp | -27.6 pp | |
| LTM Mar 2026 | -132.6% | -47.0 pp | — | |
FRNMFreenome, Inc. Common stock | — | — | — | — |
| Peer median (excluding CSTL) | -19.1% | +5.8 pp | +53.0 pp | |
Competitors are the stored peer set for CSTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 94.09M | 137.04M | 219.79M | 332.07M | 344.23M |
| Cost of Revenue | 15.82M | 32.01M | 44.98M | 60.21M | 71.03M |
| Gross Profit | 78.26M | 105.03M | 174.81M | 271.86M | 273.2M |
| Gross Margin | 83.2% | 76.6% | 79.5% | 81.9% | 79.4% |
| Research & Development | 29.65M | 44.9M | 53.62M | 52.04M | 51.85M |
| Selling, General & Admin | 86.74M | 143M | 180.15M | 200.05M | 229.32M |
| Operating Expenses | 118.34M | 177.89M | 242.78M | 263.19M | 316.01M |
| Depreciation & Amortization | 3.41M | 10.54M | 12.33M | 16M | 40.77M |
| EBITDA | (36.6M) | (58.34M) | (45.02M) | 38.14M | 11.34M |
| EBITDA Margin | -38.9% | -42.6% | -20.5% | 11.5% | 3.3% |
| Operating Income | (40.08M) | (72.86M) | (67.98M) | 8.67M | (42.81M) |
| Operating Margin | -42.6% | -53.2% | -30.9% | 2.6% | -12.4% |
| Interest Income | 68K | 3.97M | 10.62M | 12.92M | 11.77M |
| Interest Expense | 1K | 17K | 11K | 577K | 86K |
| Other Income / Expenses | 67K | 3.95M | 10.61M | 12.89M | 13.3M |
| Income Before Tax | (40.01M) | (68.9M) | (57.37M) | 21.56M | (29.51M) |
| Pre-Tax Margin | -42.5% | -50.3% | -26.1% | 6.5% | -8.6% |
| Income Tax Expense | (8.72M) | (1.77M) | 101K | 3.32M | (5.36M) |
| Net Income | (31.29M) | (67.14M) | (57.47M) | 18.25M | (24.16M) |
| Net Margin | -33.3% | -49.0% | -26.1% | 5.5% | -7.0% |
| EPS (Basic) | (1.24) | (2.58) | (2.14) | 0.66 | (0.83) |
| EPS (Diluted) | (1.24) | (2.58) | (2.14) | 0.62 | (0.83) |
| Weighted Avg Shares | 25.14M | 26.05M | 26.8M | 27.78M | 28.99M |
| Weighted Avg Shares (Diluted) | 25.14M | 26.05M | 26.8M | 29.26M | 28.99M |
Castle Biosciences, Inc.
NASDAQ:CSTL
Intrinsic Alpha fair value
Locked
Current Price
$33.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.